10/15/12 - 06:00 AM EDT
A key question is whether Abraxane will be used more than a cheaper, four-drug chemo cocktail.
10/03/12 - 10:43 AM EDT
Contributor Nate Sadeghi works the numbers and says Sarepta is still under-valued.
10/01/12 - 07:30 AM EDT
Improved treatments for pancreatic cancer challenge the relevance of Threshold's TH-302
09/24/12 - 07:00 AM EDT
A longer study blind suggests eteplirsen is really helping muscular dystrophy patients.
09/21/12 - 07:48 AM EDT
Idenix shares are dead money due to FDA safety concerns about Idenix's lead hepatitis C drug.
09/17/12 - 09:33 AM EDT
Believers in Peregrine's lung cancer drug bavituximab state their case.
09/10/12 - 11:53 AM EDT
Nate Sadeghi examines Peregrine's lung cancer drug bavituximab
08/27/12 - 10:35 AM EDT
Nate Sadeghi answers critics who think he's being too hard on Sarepta and its DMD drug eteplirsen.
08/21/12 - 07:00 AM EDT
There are legit reasons to like Sarepta Therapeutics but only if these red flags can be avoided.
08/13/12 - 09:03 AM EDT
The company's pipeline could deliver an upside surprise, plus you get a 4% dividend while you wait.